Clinical characteristics and analysis of treatment result in children with Ph‐positive acute lymphoblastic leukaemia in Poland between 2005 and 2017

Zawitkowska, Joanna; Lejman, Monika; Zaucha‐Prażmo, Agnieszka; Drabko, Katarzyna; Płonowski, Marcin; Bulsa, Joanna; Romiszewski, Michał; Mizia‐Malarz, Agnieszka; Kołtan, Andrzej; Derwich, Katarzyna; Karolczyk, Grażyna; Ociepa, Tomasz; Ćwiklińska, Magdalena; Trelińska, Joanna; Owoc‐Lempach, Joanna; Niedźwiecki, Maciej; Kiermasz, Aleksandra; Kowalczyk, Jerzy

doi:10.1111/ejh.13142

Cited by 10 publications

(9 citation statements)

References 20 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Here, we analyzed the outcome and risk factors for Ph+ ALL who underwent a joint imatinib-chemotherapy treatment, with subsequent allogeneic HCT in first CR. Our 5-year EFS and OS rates of 64.5±9.4% and 75.0±8.3% were similar to those reported by recent studies on this ALL subtype [812].…”

Section: Discussionsupporting

confidence: 91%

Outcome and prognostic factors of children with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib followed by allogeneic hematopoietic cell transplantation in first remission

et al. 2019

View full text Add to dashboard Cite

Background Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is a subset of ALL with poor prognosis. Here, we analyzed the outcomes and prognostic factors of children with Ph+ ALL who received imatinib and chemotherapy followed by allogeneic hematopoietic cell transplantation (HCT) in first complete remission (CR). Methods Thirty-one Ph+ ALL patients (female 10) diagnosed from January 2005 to December 2016 were included in the study. All patients were treated with imatinib and chemotherapy before HCT. Bone marrow (BM) evaluations included real-time quantitative polymerase chain reaction (RQ-PCR) study of the BCR-ABL1 fusion transcript. All patients received HCT with total body irradiation (TBI)-based conditioning at a median of 6.4 (range, 4.2–47.1) months from diagnosis. Results Compared to values at diagnosis, the median decrement of RQ-PCR value post-consolidation, and prior to HCT was −3.7 Log and −4.8 Log, respectively. The 5-year event-free survival (EFS) and overall survival of the patients were 64.5±9.4% (20/31) and 75.0±8.3% (23/31) respectively. Events included relapse (N=5) and death in CR post-HCT (N=6). The 5-year incidence of molecular relapse was 30.9±9.1% (9/31). An RQ-PCR decrement of at least −4 Log post-consolidation significantly predicted lower incidence of molecular relapse: 7.7±7.7% for ≥−4 Log decrement, 50.0±13.8% for <−4 Log decrement ( P =0.027). Conclusion Decrement in RQ-PCR for the BCR-ABL1 transcript that was determined after consolidation was the only significant prognostic factor for incidence of molecular relapse. In the post-induction TKI initiation setting, steadfast imatinib treatment during consolidation may allow for optimum post-HCT outcomes.

show abstract

Section: Discussionsupporting

confidence: 91%

Outcome and prognostic factors of children with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib followed by allogeneic hematopoietic cell transplantation in first remission

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Briefly, all protocols consist of induction, consolidation, reinduction and maintenance phases and CNS-directed therapy. The details of the treatment protocols are described in detail elsewhere 5–7,24–26…”

Section: Methodsmentioning

confidence: 99%

“…The diagnosis of ALL was based on the morphology, immunophenotyping, cytogenetics, and molecular features of leukemia cells. Risk group stratification according to ALL BFM-90, ALL BFM-95, ALL BFM-2000, and ALLIC-BFM 2009 protocols are as follows 5–7,24–26…”

Section: Methodsmentioning

confidence: 99%

Assessment of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: A Multicenter Study From Turkey

Tüfekçi

Evim

Güneş

et al. 2022

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Assestment of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) is of utmost importance both for risk classification and tailoring of the therapy. The data of pediatric ALL patients that received treatment with Berlin-Frankfurt-Münster (BFM) protocols were retrospectively collected from 5 university hospitals in Turkey. Of the 1388 patients enrolled in the study 390 were treated according to MRD-based protocols. MRD assestment was with real time quantitative polymerase chain reaction (qPCR) in 283 patients and with multiparametric flow cytometry (MFC)-MRD in 107 patients. MRD monitoring had upstaged a total of 8 patients (2%) from intermediate risk group to high-risk group. Univariate analysis revealed age 10 years or above, prednisone poor response, PCR-MRD ≥10−3 on day 33 and on day 78 as poor prognostic factors affecting event-free survival (EFS). Detection of >10% blasts on day 15 with MFC (MFC-high-risk group) was not shown to affect EFS and/or overall survival (log-rank P=0.339). Multiple logistic regression analysis revealed PCR-MRD ≥10−3 on day 78 as the only poor prognostic factor affecting EFS (odds ratio: 8.03; 95% confidence interval: 2.5-25; P=0.000). It is very important to establish the infrastructure and ensure necessary standardization for both MRD methods for optimal management of children with ALL.

show abstract

“…Patients received chemotherapy in accordance with the therapeutic protocols in force at the time: the ALL IC‐BFM (International Berlin‐Frankfurt‐Munster) 2002, the ALL IC‐BFM 2009, and AIEOP‐BFM ALL 2017 protocols. These are randomized trials of the IC‐BFM study group 3‐6 . Details of protocol characteristics are presented in Table 1.…”

Section: Methodsmentioning

confidence: 99%

Varicella‐zoster virus infection in the pediatric population with acute lymphoblastic leukemia in Poland

Zawitkowska

Lejman

Szmydki‐Baran

et al. 2020

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Varicella‐zoster virus (VZV) infection in pediatric hemato‐oncology patients can be a therapeutic problem when children are exposed to immunosuppression. The aim of this study is to evaluate the incidence of VZV infection, antiviral therapy and outcome in children with ALL treated in polish hemato‐oncological centers between 2012 and 2019 years. This study included medical records of 1874 patients, aged 1 to 18 years, with newly diagnosed acute lymphoblastic leukemia. During chemotherapy, 406 children out of 1874 (21.6%) experienced viral infections. The incidence of VZV infection in the whole group children with ALL was 1.8%. Among them, 34 (8.4%) patients were diagnosed with VZV infection. Thirty‐five episodes of viral infections were identified. The median time of VCV therapy was 12 days. Herpes zoster infection occurred in 24 (70.6%) children, and varicella in 10 (29.4%) ones. The average time from the start of chemotherapy to the appearance of herpes zoster was 7.26 ± 4.05 months. VZV infection occurred mainly during the maintenance therapy, the reinduction and induction phases. There was no correlation between steroid dosage or type and subsequent zoster. The total lymphocyte count of these patients on the first day of zoster was reduced. No serious complications were observed due to this infection. All patients survived. In conclusion, a low incidence of VZV infection was observed among pediatric patients with ALL in Poland. This analysis indicates that currently used therapeutic methods are effective in children with cancer and VZV infection. The main focus should be on the prevention of delayed chemotherapy.

show abstract

Clinical characteristics and analysis of treatment result in children with Ph‐positive acute lymphoblastic leukaemia in Poland between 2005 and 2017

Cited by 10 publications

References 20 publications

Outcome and prognostic factors of children with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib followed by allogeneic hematopoietic cell transplantation in first remission

Outcome and prognostic factors of children with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib followed by allogeneic hematopoietic cell transplantation in first remission

Assessment of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: A Multicenter Study From Turkey

Varicella‐zoster virus infection in the pediatric population with acute lymphoblastic leukemia in Poland

Contact Info

Product

Resources

About